People

Faculty

Reiter Yoram , Professor

Phone:  (972)-4-8292785

Building/Auditory:  3-19 Emerson

Research Papers

Research papers (peer-reviewed):

1. Reiter, Y., and Fishelson, Z.: Tumor cell lysis by Antibody-complement conjugates. Complement 4:154-157, 1987.

2. Reiter, Y., and Fishelson, Z.: Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement C3b. J. Immunol. 142: 2771-2777, 1989.

3. Fishelson, Z., Kopf, E., Pass, Y., Ross, L., and Reiter, Y.: Protein phosphorylation as a mechnism of resistance against complement damage. Prog. Immunol. 7: 205-208, 1989.

4. Yefenof, E., Benizri, R., Reiter, Y., Klein, E., and Fishelson, Z.: Potentiation of target cell sensitivity to NK lysis by antibody-C3b/iC3b heteroconjugates. J. Immunol. 144: 1538-1543, 1990.

5. Fishelson, Z., and Reiter, Y.: sublytic complement attack potentiates the resistance of tumor cells to lytic doses of complement. Compl Infl. 8: 150, 1991.

6. Reiter, Z., Reiter, Y., Fishelson, Z., Loyter, A., Nussbaum, O., and Rubinstein, M.: ClassI MHC antigens are not associated with resistance to NK cell mediated cytotoxicity. Immunobiol. 183: 23-39, 1991.

7. Reiter, Y., and Fishelson, Z.: Complement membrane attack complexes induces synthesis of large complement induced proteins (L-CIP) in human leukemic cells. Mol. Immunol. 29: 771-781, 1992.

8. Reiter, Y., Cibotariu, A., and Fishelson, Z.: Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. J. Immunol. 22: 1207-1213, 1992.

9. Brinkmann, U., Reiter, Y., Jung, S.-h., Lee, B., and Pastan, I.: A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. USA 90: 7538-7542, 1993.

10. Reiter, Y., Brinkmann, U., Webber, K.O., Jung, S.-h., Lee, B.K., and Pastan, I.: Engineering interchain disulfide bonds into conserved framework regions of Fv fragment: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stablilized Fv. Protein Eng. 7: 697-704, 1994.

11. Reiter, Y., Brinkmann, U., Kreitman, R.J., Jung, S.-h., Lee, B.K., and Pastan, I.: Stabilization of the Fv fragments in recombinant immunotoxins by disulfide-stabilized Fv fragment. Biochemistry 33: 5451-5459, 1994.

12. Reiter, Y., Pai, L., Brinkmann, U., and Pastan, I.: Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 54: 2714-2718, 1994.

13. Reiter, Y., Kreitman, R.J., Brinkmann, U., and Pastan, I.: Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti Tac(Fv) fragment and a truncated Pseudomonas exotoxin. Int. J. Cancer. 58: 142-149, 1994.

14. Reiter, Y., Brinkmann, U., Jung, S-h, Lee, K., Kasprzyk, P.G., King, C.R., and Pastan, I.: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide-stabilization of the Fv fragment. J. Biol. Chem. 269: 18327-18331, 1994.

15. Reiter, Y., Kurucz, I., Brinkmann, U., jung, S.h., Lee, B., Segal, D.M., and Pastan, I.: Construction of a disulfide stabilized TCR Fv fragment indicates that antibody and TCR Fv frameworks are very similar in structure. Immunity 2: 281-287, 1995.

16. Webber, K.O., Reiter, Y., Brinkmann, U., Kreitman, R.J., and Pastan, I.: Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol. 32: 249-258, 1995.

17. Benhar, I., Reiter, Y., Pai,.L., and Pastan,I.: Administration of disulfide-stabilized B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuos infusion increases their efficacy in curing human tumor xenografts in mice. Int. J. Cancer. 62: 351-355, 1995.

18. Reiter, Y., Ciobotariu, A., Jones, J., Morgan, B.P., and Fishelson, Z.: Complement membrane attack complex, perforin, and bacterial exotoxin induce in K562 cells calcium-dependent cross-protection from lysis. J. Immunol. 155: 2203-2210, 1995.

19. Reiter, Y., Brinkmann, U., Jung, S-h., Lee. B., and Pastan, I.: Disulfide-stabilization of antibody Fvs: computer prediction and experimental evaluation. Protein Eng. 8: 1323-1331, 1995.

20. Reiter, Y., Wright, A.F., and Pastan, I.: Recombinant single-chain and disulfide-stabilized Fv immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Int. J. Cancer. 67: 113-123, 1996.

21. Reiter, Y., Brinkmann, U., Lee, B.K., and Pastan, I.: Engineering antibody Fv fragments for cancer diagnosis and therapy. Nature Biotech. 14: 1239-1245, 1996.

22. Reiter, Y., DiCarlo, A., Engberg, J., and Pastan, I.: Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to MHC/peptide class I complexes with T-cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 94: 4631-4636, 1997.

23. Reiter, Y., and Pastan, I: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends in Biotech. 16: 513-520, 1998.

24. Reiter, Y., Schuck, P., Boyde, L.F., and Plaksin, D.: Antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules and their characterization. J. Mol. Biol. 1999.

25. Denkberg, G., Cohen, C.J., Segal, D., Kirkin A.,and Reiter, Y.: Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 30: 3522-3532, 2000.

26. Reiter, Y.: Recombinant immunotoxins for targeted cancer cell therapy. Adv. Cancer Res. 81: 93-124, 2001.

27. Jurianz, K., Ziegler, S., Donin, N., Reiter, Y., Fishelson, Z., and Kirschfink, M.: K562 erthtoleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 93:848-854, 2001.

28. Niv, R., Cohen, CJ., Denkberg, G., Segal, D., and Reiter, Y.: Antibody Engineering for Targeted Drug delivery: Applications for Recombinant Fv Immunotoxins and Fv fragments in Cancer Therapy and Diagnosis. Current Pharmaceutical Biotechnology 2: 19-46, 2001.

29. Niv, R., Pirak, E., Segal,D.,Assaraf, Y., and Reiter, Y. : Targeting multi drug resistance (MDR) tumor cells with a recombinant single-chain Fv fragment directed to P-glycoprotein. Int. J. Cancer 94: 864-872, 2001.

30. Denkberg, G., Cohen, C.J., and Reiter, Y.: Critical role for CD8 in binding of MHC-peptide complexes to TCR: CD8 antibodies block specific binding of human tumor-specific MHC/peptide tetramers to T-cell receptor. J. Immunol. 167: 270-276, 2001

31. Cohen, CJ, Denkberg, G and Reiter, Y.: Generation of recombinant immunotoxins for specific targeting of tumor related peptides presented by MHC molecules. Recominant Antibody Technology for Cancer Therapy. Methods. Mol. Biol. 207: 269-282, 2002.

32. Benjamin L, Plaksin, D., and. Reiter, Y.: Isolation of single-domain VH antibody fragments from phage display libraries. Recominant Antibody Technology for Cancer Therapy. Methods. Mol. Biol. 207: 133-143, 2002.

33. Niv, R., Segal, D., and Reiter, Y..: Construction of recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer targeting. Recominant Antibody Technology for Cancer Therapy. Methods. Mol. Biol. 207: 255-268, 2002.

34. Denkberg, G., Cohen, CJ., Lev, A., Chames, P., Hoogenboom, H., and Reiter, Y.: Direct visualization of distinct T cell epitopes derived from a melanoma tumor associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA. 99: 9421-9426, 2002.

35. Lev,A., Denkberg, G., Cohen, CJ., Tzukerman, M., Skorecki, KL., Chames, P., Hoogenboom, H.,and Reiter, Y.: Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 62: 3184-3194, 2002.

36. Lev, A., Novak, H., Segal, D., and Reiter, Y.: Recruitment of CTL activity by tumor-specific, antibody-mediated targeting of single-chain class I MHC-peptide complexes J. Immunol. 169: 2988-2996, 2002.

37. Denkberg, G., Kalchevsky, E., and Reiter, Y: Specific modification of a tumor-derived peptide at an HLA-A2 anchor residue can influence the conformation of the MHC-peptide surface area: probing with T-cell receptor-like recombinant antibodies. J. Immunol. 169: 4399-407, 2002.

38. Cohen, CJ., Hoffman, N., Farago, M., , Hoogenboom, HR., Eisenbach, L., and Reiter, Y.: Direct detection and quantitation of a distinct T cell epitope derived from tumor-specific epithelial cell-associated mucin (MUC1) using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 62: 5835-5844, 2002.

39. Apel, M., Ellenhorn, J.D., Diamond, D.J. and Reiter, Y.: A functional T cell Receptor Fv capable of specific targeting to antigen presenting cells. Cancer Immunol. Immunother. 51: 565-573, 2002.

40. Cohen, CJ., Sarig, O.,Yamano,Y.,Tomaru, U., Jacobson, S., and Reiter, Y.: Direct Phenotypic Analysis of human MHC Class I Antigen Presentation: Visualization, Quantitation, and In Situ Detection of Human Viral Epitopes Using Peptide-Specific, MHC-restricted Human Recombinant Antibodies. J. Immunol. 170: 4349-4361, 2003.

41. Cohen C.J., Denkberg, G., Schiffenbauer, Y., Berke, G., and Reiter, Y.: Simultaneous Monitoring of Binding to and Activation of Tumor-specific T Lymphocytes by Peptide-MHC. J. Immunol. Methods 277: 39 – 52, 2003.

42. Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., and Reiter, Y.: Selective targeting of melanoma and antigen-presenting cells using a recombinant antibody with T-cell receptor-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 171:2197-2207, 2003.

43. Cohen C.J., Denkberg, G., Lev, A., Epel, M., and Reiter, Y: T cell receptor-like recombinant antibodies: New tools for the study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recog. 16: 324-332, 2003.

44. Biddison, W.E., Turner, R.V., Lev, A., Cohen, CJ., and Reiter, Y.: Tax and M1 peptide/HLA-A2-specific Fabs and T Cell Receptors Recognize non-identical Structural Features on peptide/HLA-A2 complexes. J. Immunol. 171: 3064-74 2003.

45. Haus-Cohen, M., Assaraf, Y., Benhar, I., and Reiter, Y.: Disruption of P-glycoprotein (Pgp) Anticancer Drug Efflux Activity by a Small Recombinant Single-chain Fv Antibody Fragment Targeted to an Extracellular Epitope. Int. J. Cancer 109: 750-758, 2004.

46. Oh, S., Terabe, M., Pendleton, D.C., Bhattacharyya, A., Bera, T., Epel, M., Reiter, Y., Phillips, J., Linehan, J., Pastan, I., and Berzofsky, J.A.: Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. 64: 2610-8, 2004.

47. Binyamin, L., Assaraf, Y.G., and Reiter, Y.: Targeting an extracellular epitope of Multi Drug Resistance Protein 1 (MRP1) by a small recombinant single-chain Fv antibody. Int. J. Cancer 110:882-890, 2004.

48. Yamano, Y., Cohen, C.J., Tomaru, U., Li, H-C., Takenouchi, N., Biddison, W., Reiter, Y., and Jacobson, S.: Increased expression of HTLV-1 Tax11-19 peptide/HLA-A*201 complexes on CD4+CD25+ T cells detected by TCR-like antibodies in patients with HTLV-1 associated neurologic disease. J. Exp. Med. 199: 1367-1377, 2004.

49. Zehn, D., Cohen, C.J., Reiter, Y., and Walden, P.: Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Euro. J. Immunol. 34:1551-1560, 2004.

50. Lev, T., Noy, R., Oved, K., Novak, H., Segal, D., Walden, P., Zehn, D., and Reiter, Y.: Tumor-Specific Antibody-Mediated Targeting of MHC-Peptide Complexes Induces Regression of Human Tumor Xenografts In Vivo. Proc. Natl. Acad. Sci. USA. 101: 9051-9056, 2004.

51. Held, G., Matsuo, M., Gnjatic, S., Epel, M., Ritter, G., Yull, S., Tai , T., Cohen, C.J., Old, L.J., Pfreundschuh, M., Reiter, Y., Hoogenboom, H.R., and Renner, C.: Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide-MHC specific antibody fragments. Eur. J. Immunol. 34: 2919-2929, 2004.

52. Oved, K., Lev, A., Noy, R., Segal, D., and Reiter, Y.: Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 54:867-79, 2005.

53. Kummer, M., Lev, A., Reiter, Y., and Biedermann, B.C.: Vascular Endothelial Cells Have Impaired Capacity to Present Immunodominant, Antigenic Peptides - a Mechanism of Cell-type Specific Immune Escape. J. Immunol. 174: 1947-1953, 2005.

54. Binyamin, L., Assaraf, Y.G., and Reiter, Y.: ATP-dependent binding of a scFv antibody fragment directed to an extracelluar epitope of the multi drug resistance protein 1 (MRP1) on live cells: implication for ATP-dependent conformational changes. Int. J. Cancer. 116: 703-9, 2005.

55. Tzukerman M., Rosenberg T., Reiter I, Ben-Eliezer S., Denkberg G., Coleman R., Reiter Y., and Skorecki K. (2006). The Influence of a Human Embryonic Stem Cell Derived Microenvironment upon Targeting of Human Solid Tumor Xenografts. Can. Res. 66: 3792-3801, 2006.

56. Artzi, A., Benhar, I, Reiter, Y and Sivan, U.: Antibody Molecules Discriminate between Crystalline Facets of a Gallium Arsenide Semiconductor. Nano letters. 6:1870-1874, 2006.

57. Zehn, D., Cohen, C.J., Reiter, Y., and Walden, P. Efficiency of peptide presentation by dendritic cells compared to other cell types: Implications for cross-priming. Int. immunol. 18:1647-54, 2006.

58. Machlenkin, A., Azriel-Rosenfeld, R., Volovitz, A, Vadai, E., Lev, A., Paz, A., Goldberger, O.,Tzehoval, E., Reiter,Y., Benhar, I., and Eisenbacc, L. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother. 56:217-26, 2007.

59. Novak, H., Wels, W., Zehn, D., and Reiter, Y.: Antibody- mediated selective targeting of antigenic MHC-peptide complexes induces efficient killing in vitro and in vivo of EGFR1-expressing tumor cells by tumor or viral-specific cytotoxic T lymphocytes. Int. J. Cancer 120:329-36. 2007.

60. Oved, k., Ziv, O., Jacob-Hirsch, J., Novak, H., Makler, O., Denkberg, G, Sinik, K., Segal, D., Noy, R., Gefen-Dor, C., Amariglio, N., Rechavi, G.,and Reiter, Y. A Novel Post Priming Regulatory Check Point of Effector/Memory T cells Dictated Through Antigen Density Threshold-dependent Anergy. J. Immunol. 178:2307-17, 2007.

61. Denkberg, G.,Stronge, VS.,Zahavi, E.,McCarthy, C., Shepherd, D., Illarionov, PA., van der Merwe, A., , Besra, BS. , Cerundolo,V., and Reiter, Y. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules. J. Immunol. 38: 451-9, 2008.

62. McCarthy, C., Shepherd, D., Fleire, S., Stronge, V., Koch, M., Illarionov, P., Bossi, G., Salio, M., Denkberg, G., Mathew, B., Schmidt, R., Reiter, Y., Griffiths, G., van der Merwe, A., Besra, G., E. Jones, Y., Batista, F., and Cerundolo, V. The length of lipids bound to human CD1d molecules modulates the affinity of the NKT Cell Receptor and NKT cell activation. In press, J. Exp. Med. 204:1131-44, 2007.

63. Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, and Reiter Y.:Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res. 68:6360-6367, 2008.

64. Zohar O, Reiter Y, Bennink JR, Lev A, Cavallaro S, Paratore S, Pick CG, Brooker G, and Yewdell JW. Cutting edge: MHC class I-Ly49 interaction regulates neuronal function. J Immunol. 180:6447-6451, 2008.

65. Lev A, Takeda K, Zanker D, Maynard JC, Dimberu P, Waffarn E, Gibbs J, Netzer N, Princiotta MF, Neckers L, Picard D, Nicchitta CV, Chen W, Reiter Y, Bennink JR, and Yewdell JW. The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity. 28:787-798, 2008.

66. Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, Berzofsky J, Reiter Y. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol. 38:1706-1720, 2008.

67. Artzy-Schnirman A, Brod E, Epel M, Dines M, Hammer T, Benhar I, Reiter Y, and Sivan U. A Two-State Electronic Antigen and An Antibody Selected to Discriminate Between These States. Nano Lett. 8:3398-403 2008.

68. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, Reiter Y, Banchereau J, and Ueno H. Functional Specializations of Human Epidermal Langerhans Cells and CD14(+) Dermal Dendritic Cells. Immunity. 29:497-510. 2008.

69. Pellicciotta, L., Cortez-Gonzalez, X., Sasik, R., Reiter, Y.,Hardiman,G., Langlade-Demoyen, P. Zanetti, M., Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res. 68:8085-93 2008.

70. Michaeli, Y, Denkberg, G, Chang, C.S., Lanzly. E, Romero, P., and Reiter, Y: Expression hierarchy of T cell epitopes derived from melanoma differentiation antigens: Unexpected high level presentation of Tyrosinase-derived peptide-MHC complexes revealed by peptide-specific, MHC-restricted recombinant antibodies. J. Immunol. 182: 6328-6341, 2009.

71. Oved, K, Eden, E., Akerman, M., Mandel-Gutfreund, Y., Alon, U., Besser, M., and Reiter, Y., Predicting and controlling the reactivity of immune cell populations against cancer. Mol. Sys. Biol. 5:265, 2009.Science Editor's Choice, Science 324:568, 2009.

72. Besser M, Schallmach E, Oved K, Treves A, Markel G, Reiter Y, Schachter J. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Cytotherapy 16:1-12, 2009.

73. Mekler, O, Oved, K., Wolf, D., and Reiter, Y: Dynamics of HLA-A2/pp65 epitope expression on Cytomegalovirus-infected cells as revealed by novel recombinant T-cell receptor-like antibodies. Eur. J. Immunol. 40: 1552-1562, 2010.

74. Klechevsky, E., Flamar, A.L., Cao, Y., Liu, M., Thompson-Snipes, L., O'Bar, A.,Zurawski, S., Reiter, Y., Zurawski, G., Banchereau, J. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 116:1685-97, 2010.

75. Bronner V, Denkberg G, Peled M, Elbaz Y, Zahavi E, Kasoto H, Reiter Y, Notcovich A, Bravman T. Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system. Anal Biochem. 406:147-56, 2010.

76. Dahan, R., Vandenbark, A.A., and Reiter, Y: TCR-like antibodies distinguish conformational and functional differences in auto-reactive idiotopes present on two vs. four-domain MHC class II/peptide complexes. 2010

Review papers:

 

81. Reiter, Y., and Pastan, I.: Antibody engineering of recombinant Fv-immunotoxins for improved targeting of cancer. Clin. Cancer Res. 2: 245-252, 1996.

82. Reiter, Y., Brinkmann, U., Lee, B.K., and Pastan, I.: Engineering antibody Fv fragments for cancer diagnosis and therapy. Nature Biotech. 14: 1239-1245, 1996.

83. Reiter, Y.: Recombinant immunotoxins for targeted cancer cell therapy. Adv. Cancer Res. 81: 93-124, 2001.

84. Noy, R., Epel, M., Haus-Cohen, M., Klechevsky, E., Makler, O., Michaeli, Y., Denkberg, G., and Reiter, Y.: T cell receptor-like antibodies: novel reagents for clinical immunology and immunotherapy. Expert. Rev. Anticancer Ther. 5: 523-536, 2005.

85. Shadel, O., and Reiter, Y.: Antibodies and their fragments as anticancer agents. Curr Pharm Des. 12: 363-378, 2006.

86. Lev, T., and Reiter, Y.: Recombinant MHC molecules. Current Pep. Prot. Sci. In press 2006.

87. Cohen, C.J., Denkberg, G., Lev, A., and Reiter, Y.: T cell receptor-like recombinant antibodies: New tools for the study antigen presentation and TCR-peptide-MHC interactions. Histology and Histopathology In press 2006.

88. Denkberg, G., and Reiter, Y.: Recombinant antibodies with T-cell receptor-like specificity: Novel tools to study MHC class I presentation. Autoimmunity Rev. 5: 252-257, 2006.

89. Michaeli, Y., and Reiter, Y: Optimized Fc variants with enhanced effector function. Expert Opin. Ther. Patents 16:1449-1452, 2006.

90. Tzafir, Y, Michaeli, Y., and Reiter, Y: Novel Antibodies as Anti-cancer Agents. Oncogene Reviews. 26:3714-33, 2007.

91. Dahan, R, and Reiter, Y: TCR-like antibodies: clinical applications for therapy and diagnosis. Expert. Rev. Mol. Med. 2011.

Book Chapters:

 

92. Reiter, Y., and Fishelson, Z.: Killing of human tumor cells by antibody-C3b conjugates and human complement. In Radwell, J.D. (Ed.): Targeted Antibodies for Diagnosis and Therapy. New York, Marcel Dekker Inc., 1989, pp. 119-135.

93. Fishelson, Z., and Reiter, Y.,: Monoclonal Antibody-C3b conjugates: killing of K562 cells and selection of a stable complement resistant variant. In Grogoman, J., Evans, C., and Golde, D. (Eds.):Mechanisms of Action and Therapeutic Application on Biologicals in Cancer and Immune Deficiency Disorders. New York, Alan R. Liss, Inc., 1989, pp. 272-282.

94. Reiter, Y., Lee, B.K., and Pastan, I.: Disulfide stabilized Fvs. In: Antibody Engineering: technologies and applications. IBC Biomedical Library Series, IBC press. Pp. 147-169, 1996.

95. Reiter, Y., Dicarlo, A., Engberg., and Pastan, I.: Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to MHC/peptide class I complexes with T-cell receptor-like specificity. In Antibody engineering new technologies and applications IBC Biomedical library IBC press pp.235-245,1997.

96. Reiter, Y. Denkberg, G, Cohen, CJ.: Engineering immunotoxins for improving their therapeutic activity. In Chimeric toxins: Mechanisms of action and therapeutic applications. Lazarovici, P., and Lorberboum-Galski, H., Eds.Harwood Academic Pub. pp 99-134, 2002.

97. Benhar, I., and Reiter, Y.: Phage display of single-chain antibody (scFv) constructs. Current Protocols in Immunology. 48:10.4 pp59-87, 2002.

98. Reiter, Y. and Lev, A.,: Immunotoxins in cancer therapy. In Cancer Immune Therapy: Experiences and Future Directions, Gernot Stuhler and Peter Walden Eds. Wiley-VCH pp. 347-379, 2002.

99. Lev, A., Denkberg, G., Cohen, CJ., Hoogenboom, HR, and Reiter, Y: Unexpected high frequency of Recombinant Antibodies endowed with the antigen-specific MHC-restricted specificity of T Cells isolated from a lrarge naïve human library. Tumor Microenvironment: Progression, Therapy and Prevention. Monduzzi Editore press pp. 163-167, 2002.

100. Lev, A., Novak, H., Segal, D., and Reiter, Y.: Directing cytotoxic T cells to tumor cells by Antibody-mediated Targeting of Single-chain Class I MHC-peptide complexes. Tumor Microenvironment: Progression, Therapy and Prevention Monduzzi Editore press. Pp. 169-174, 2002.

101. Reiter, Y. and Lev, A. Immunotoxins and recombinant immunotoxins in cancer therapy. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Ed. R. Meyer, Wiley-VCH pp 497-529, 2004.